Detalhe da pesquisa
1.
Rifaximin-α reduces gut-derived inflammation and mucin degradation in cirrhosis and encephalopathy: RIFSYS randomised controlled trial.
J Hepatol
; 76(2): 332-342, 2022 02.
Artigo
em Inglês
| MEDLINE | ID: mdl-34571050